Chemomab Therapeutics (CMMB) Stock Price, News & Analysis

Company Overview

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Key Stats

• Today's Range: $1.09 to $1.12
• 50-Day Range: $1.10 to $1.40
• 52-Week Range: $0.87 to $2.55
• Volume: 243,080 shs
• Average Volume: 225,761 shs
• Market Capitalization: $20.75 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.50
• Consensus Rating: Buy

Chemomab Therapeutics Stock Analysis - MarketRank™

Chemomab Therapeutics scored higher than 44% of companies evaluated by MarketBeat, and ranked 600th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Chemomab Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Chemomab Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Chemomab Therapeutics are expected to grow in the coming year, from ($1.00) to ($0.70) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Chemomab Therapeutics is -1.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Chemomab Therapeutics is -1.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Chemomab Therapeutics has a P/B Ratio of 1.53. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.94% of the float of Chemomab Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Chemomab Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Chemomab Therapeutics has recently increased by 2.61%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Chemomab Therapeutics does not currently pay a dividend.

Dividend Growth

Chemomab Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.94% of the float of Chemomab Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Chemomab Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Chemomab Therapeutics has recently increased by 2.61%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for CMMB on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Chemomab Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

11.91% of the stock of Chemomab Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

46.05% of the stock of Chemomab Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CMMB Stock Analysis - Frequently Asked Questions

How have CMMB shares performed this year?

Chemomab Therapeutics' stock was trading at $1.81 at the start of the year. Since then, CMMB stock has decreased by 39.2% and is now trading at $1.10.

How were Chemomab Therapeutics' earnings last quarter?

Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) released its earnings results on Thursday, May, 15th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.06.

How do I buy shares of Chemomab Therapeutics?

Shares of CMMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Chemomab Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Chemomab Therapeutics investors own include Arista Networks (ANET), Broadcom (AVGO), CrowdStrike (CRWD), ServiceNow (NOW), NVIDIA (NVDA), Meta Platforms (META) and Adobe (ADBE).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 7/23/2025
• Next Earnings (Estimated): 8/20/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CMMB
• CIK: 1534248
• Web: www.chemomab.com
• Phone: 972-77-331-0156
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Chemomab Therapeutics: $8.50
• High Price Target: $10.00
• Low Price Target: $7.00
• Potential Upside/Downside: +672.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.76)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$13.94 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -106.70%
• Return on Assets: -82.18%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.33
• Quick Ratio: 5.33

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.72 per share
• Price / Book: 1.53

Miscellaneous

• Outstanding Shares: 18,860,000
• Free Float: 16,611,000
• Market Cap: $20.75 million
• Optionable: Not Optionable
• Beta: 0.43